AVXL - Anavex Life Sciences Corp.

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Anavex Life Sciences GAAP EPS of -$0.11 beats by $0.04
• Anavex Life Sciences Q1 2024 Earnings Preview
• Anavex initiates Phase 2 study for schizophrenia drug candidate
• Anavex drops as Phase 2/3 trial for Rett syndrome candidate fails
• Anavex gets EMA green light to submit blarcamesine application for Alzheimer's
• Anavex Life Sciences falls after Q4 pipeline update
• Anavex Life Sciences GAAP EPS of -$0.12
• Anavex gains as EU filing for Alzheimer’s drug starts
• Anavex gains on preventative effects of Alzheimer’s drug
• Alzheimer's drug developers get lift from Anavex results
• Anavex Alzheimer's candidate slows cognitive decline in key study
• Researchers study weight loss drugs in dementia and addiction
• ZS, FLNC and IHRT are among after hour movers
• Anavex Life Sciences GAAP EPS of -$0.14 beats by $0.03
• Anavex lead candidate shows promise for Rett syndrome
• Anavex taps Partex to use AI for drug development
• Alzheimer’s disease market expected to reach $14B globally in 2030
• Anavex gains compositions patent for Alzheimer's drug candidate
• Biogen’s new Alzheimer’s drug to raise annual Medicare costs by up to $5B – study
• Lundbeck, Otsuka's Rexulti wins FDA approval for agitation linked with Alzheimer's